The influence of P2Y₁₂ gene polymorphisms on clopidogrel therapy in patients after percutaneous coronary intervention.

ABSTRACT: Aim: We aimed to define the influence of P2Y12 polymorphisms (rs6801273, rs2046934, and rs6809699), diabetes, hypertension, obesity, hypercholesterolemia, statins intake, and smoking habit on clopidogrel therapy in patients undergoing percutaneous coronary intervention.Materials & methods: We used PCR-RFLP and PCR-ASO for P2Y₁₂ genotype analysis. The effectiveness of the therapy was measured with the VerifyNow method and defined in platelet reactivity units.Results: Studied polymorphisms had no statistically significant influence on PRU before (PRU⁰) and 6 months (PRU⁶) after the procedure. H1/H1 diabetic carriers had significantly higher PRU⁶ values than patients without diabetes. Obese H1/H2 subjects had significantly lower

SUBMITTER: Pawlak K 

PROVIDER: S-EPMC11457605 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature